Bristol Myers Squibb selected Houston as the site for a new, state-of-the-art multi-modal manufacturing campus, representing an approximately $2.3 billion investment designed to accelerate the delivery of next-generation medicines to patients.
The campus, at Generation Park in Houston, will create nearly 500 skilled jobs and is designed to grow in scale, capability and workforce for decades to come.
The selection of Houston marks a significant milestone in BMS’ $40 billion commitment to invest in the United States over five years across research and development, technology and domestic manufacturing.
From day one, the Houston campus will be modular and multi-modal. Its modular design allows BMS to add and reconfigure manufacturing capacity as needed, reflecting BMS’ current and future pipeline. Its multi-modal capabilities allow BMS to manufacture multiple types of medicines – such as small molecules, biologics, and antibody-drug conjugates – across a range of disease areas, supporting drug product and finished goods manufacturing from late development through launch. This flexibility ensures the campus can evolve to meet patient needs well into the future.
“This investment reflects our confidence in America’s continued leadership in biopharmaceutical innovation,” said Christopher Boerner, Ph.D., Board Chair and CEO of Bristol Myers Squibb, in a press release. “As part of our $40 billion commitment to the United States, we’re building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life.”
Bristol Myers Squibb’s approximately 600,000 square foot manufacturing campus in Houston, Texas will be a modular, multi-modal campus designed for flexibility and long-term growth. Its architecture allows new manufacturing capabilities to be brought online rapidly as pipeline and commercial needs evolve. The campus is also built for adaptability, with configuration flexibility that anticipates future advances in digital integration and automation, ensuring the site remains at the frontier of biopharmaceutical development and manufacturing technology as capabilities continue to evolve. BMS envisions this site growing in scale and capability well beyond its opening configuration.
